Recent Articles from Investor Brand Network

A new report from the Missouri Cannabis Trade Association says many retailers that advertise legal hemp products are instead selling cannabis products with high THC levels. The group’s findings come from laboratory tests on 55 products purchased at gas stations, smoke shops, and stores that market themselves as hemp or CBD sellers.

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

As tech giants pour billions into traditional data center expansion, BluSky AI (OTC: BSAI) is uniquely positioned with its innovative Neocloud platform and modular SkyMod technology. “BluSky AI is focused to democratize access to enterprise-grade AI infrastructure through a fundamentally different approach, delivering compute power in months rather than years,” reads a recent article. “BluSky AI’s trajectory starts with its revolutionary Neocloud platform, built for AI from the ground up. BluSky AI’s initial Neocloud will consist of 150 MW with 20 planned locations spread across the U.S. With locations from 9 MW to 50 MW located closer to businesses to facilitate low latency-millisecond inferencing… The fabric supporting BluSky AI’s Neocloud will be the deployment of SkyMod modular data centers called ‘AI Factories.’ Each SkyMod is a proprietary unit prebuilt and tested in a controlled environment before being shipped for plug and play installation. The SkyMod One AI Factory supports 1 MW of compute capacity. Multiple SkyMods can be networked on a single location to support up to 60 MW and will be interconnected throughout the future defined 20 locations in the Neocloud platform.”

Disseminated on behalf of ShelfieTech Ltd. (CSE: SHLF) (OTCQB: SHLFF) and may include paid advertising.

Bitcoin and crypto-related shares extended their nearly two-month slide on Dec. 1, mirroring a broader retreat in tech shares that many investors argue have climbed too far, too fast.

Disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising.

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

CNS Pharmaceuticals (NASDAQ: CNSP) was featured in a BioMedWire Podcast discussing its sharpened focus on glioblastoma multiforme (“GBM”), one of the deadliest and least treatable forms of cancer. In the interview, CEO John Climaco said of GBM, “Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.”

Beeline Holdings (NASDAQ: BLNE) was featured in a recent article that discussed its fast-growing digital mortgage platform and the company’s efforts to redefine the path to homeownership. The piece reads “Its AI-enabled proprietary platform can scale loan processing volumes rapidly while maintaining operational efficiency. By automating much of the underwriting and documentation process, Beeline can approve loans within minutes and close them in as few as 14 to 21 days, less than half the industry average. The platform’s design also caters to a changing borrower demographic. According to National Mortgage Professional, only 26.1% of Gen Z and 54.9% of Millennials owned homes in 2024, reflecting limited access to affordable mortgages. Beeline’s tools, including its AI decision engine and chatbot ‘Bob,’ aim to close that gap, giving buyers near-instant certainty about mortgage eligibility.”

Parler Technologies has initiated a Regulation D, Rule 506(c) private placement to raise up to $50 million, with the option to increase to $100 million, ahead of a planned Nasdaq or NYSE public offering targeted for late 2026 or early 2027. Managed by Digital Offering, the raise allows accredited investors to participate in Parler’s rebuilt, fully sovereign technology ecosystem, which includes Triton Cloud, Edgecast CDN, PlayTV, Kyvo, Cartix, and ParlerNews operating on an integrated blockchain protocol layer. The company says its independent infrastructure significantly reduces operating costs and enhances creator earnings while enabling a unified creator-commerce platform designed to support long-term growth and future public-market positioning.

Oncotelic Therapeutics (OTCQB: OTLC), reports that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company’s intravenous Deciparticle(TM) formulation of everolimus. The biomarker framework, to be presented at the 2025 San Antonio Breast Cancer Symposium, is based on analysis of more than 9,000 tumor samples across 20 cancer types and represents the first prospective selection strategy for IV everolimus. Data show that mTORC2-dominant tumors — including HR+/HER2- breast, lung adenocarcinoma, gastric, renal, ovarian, AML and T-cell malignancies — exhibit heightened mTOR dependency and predicted sensitivity to Sapu003, which overcomes limitations of oral everolimus through higher tissue penetration, reduced GI accumulation and preserved metabolic specificity.

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) and may include paid advertising.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

Disseminated on behalf of Silvercorp Metals Inc. (NYSE-A/TSX: SVM) and includes paid advertisement.

Disseminated on behalf of New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) and includes paid advertisement.

Artificial intelligence (“AI”) is accelerating across nearly every sector, reshaping how companies innovate, compete, and protect their digital assets. Datavault AI Inc. (NASDAQ: DVLT), a data-centric enterprise AI company, is working to ensure organizations of all sizes can deploy, secure and scale AI systems built on trustworthy data. The company’s platform helps transform fragmented, unstructured information into actionable digital assets, enabling businesses to implement AI more efficiently and responsibly.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that its Nu.Q® NETs H3.1 assay has been chosen as the sole biomarker for “DETECSEPS,” a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million (~$7.3 million) grant, aims to transform emergency care for patients with infection and risk of sepsis progression.

This article has been disseminated on behalf of McEwen Inc. and may include paid advertising.

This article has been disseminated on behalf of Foremost Clean Energy Ltd. and may include paid advertising.

This article has been disseminated on behalf of Shelfie-Tech Ltd. and may include paid advertising.

This article has been disseminated on behalf of New Pacific Metals Corp. and may include paid advertising.

The start of this week saw the price of gold surge to a new high, bolstered by a weakening dollar and increasing expectations of rate cuts by the Fed. The precious metal’s price hit $4,241.27 an ounce, its highest level since October. Gold futures for February also rose to $4,274.80 an ounce.

Norway saw almost all new car registrations go electric in November. The country recorded 19,427 battery-only vehicles out of 19,899 newly registered passenger cars, pushing the EV share to 97.6 percent and producing one of the largest monthly registration totals the market has seen.

A newly published study shows that the fight against cancer could be boosted by considering approaches that seek to disrupt the mechanisms through which tumor cells respond to damage to their DNA. Targeting these pathways could make immunotherapy more effective for a lot more people.

AI has shifted from a side topic to a central theme in the biopharma world . Over the past year, multibillion-dollar AI collaborations have become routine, chipmakers have found new demand in drug research, and industry events have turned into forecasting sessions about how machine learning might reshape the lab.

Mitigating talent shortage challenges during an energy transition is a major issue for many firms . As renewable energy adoption accelerates, companies are finding it difficult to secure enough skilled professionals to keep up with demand. The rapid growth of solar, wind, and storage projects is outpacing the workforce, leaving a gap in both technical expertise and operational know-how. Without a solution, project timelines and sustainability goals are at risk.

eCommerce has changed quickly, and 2025 looks nothing like the early days when brands could pack orders from a small room and ship them out with little stress. Today, online shopping has higher demand, faster delivery standards, and far more competition. Because of this, many brands are rethinking how they manage the behind-the-scenes work that keeps orders moving. More companies are choosing to outsource their fulfillment operations, and this shift is becoming a core part of modern e-commerce strategy.

Massimo Group (NASDAQ: MAMO) has established Massimo AI Technology Inc., a wholly owned subsidiary created to advance the company into industrial and service robotics while supporting its long-term technology roadmap. The new division will develop practical automation and warehouse-assistance platforms, build a dedicated robotics supply and manufacturing foundation, and leverage Massimo’s existing strengths in electric systems and global operations. Leadership says the initiative broadens the company’s technology base, opens potential entry into high-growth automation sectors, and supports diversified long-term revenue opportunities.

BioMedWire Editorial Coverage : Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ: SNGX) ( profile ), a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”), where it is currently running the final confirmatory trial necessary before seeking global marketing authorization. As the Trump administration pursues new health-policy measures focused on chronic and rare diseases, Soligenix’s programs are positioned at a pivotal crossroads of scientific innovation and national healthcare goals. The company is working alongside several prominent leaders in the pharmaceutical and life sciences sectors, including AMGEN Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Citius Oncology Inc. (NASDAQ: CTOR) and…

A surge in hemp-derived THC products that reshaped convenience store shelves and fueled a fast-growing market appears to be heading toward a sharp slowdown. Tucked inside the bill that brought an end to the recent federal shutdown is a clause that would outlaw hemp-derived THC products nationwide.

Gloo (NASDAQ: GLOO), a technology platform serving the faith and flourishing ecosystem, priced its initial public offering of 9,100,000 shares of Class A common stock at $8 per share and granted underwriters a 30-day option to purchase up to 1,365,000 additional shares. Trading is expected to begin on the Nasdaq Global Select Market under the symbol GLOO, with the offering slated to close Nov. 20, 2025, subject to customary conditions. Roth Capital Partners is serving as sole book-running manager, with The Benchmark Company, Craig-Hallum Capital Group, Lake Street Capital Markets, Loop Capital Markets, and Texas Capital Securities acting as co-managers.

Safe Pro Group (NASDAQ: SPAI), a mission-driven provider of AI-powered defense and security solutions, is aligned with a major federal shift as the War Department moves to acquire roughly 300,000 low-cost drones under President Trump’s “Unleashing American Drone Dominance” initiative. The department’s new request for information outlines a $1 billion procurement program beginning in early 2026 that will fund four production “gauntlets,” starting with 12 vendors delivering 30,000 drones at $5,000 per unit and scaling toward 150,000 units at reduced costs. Secretary of War Pete Hegseth said the program aims to rebuild U.S. industrial capacity, integrate unmanned systems into all combat training, and ensure the military can field inexpensive battlefield drones at scale—tens of thousands in 2026 and hundreds of thousands by 2027.

Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8 million registered offering consisting of 13,333,333 Class A ordinary shares at $0.60 per share and warrants to purchase 26,666,666 additional shares at 110 percent of the offering price with a 120-day term. Gross proceeds totaled $8 million before expenses, and the company plans to use the net proceeds to support business expansion, R&D, river-water quality management initiatives, wastewater treatment technology upgrades, and talent recruitment. The offering was conducted on a reasonable best-effort basis, with D. Boral Capital LLC serving as placement agent.

Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that Sapu003, its intravenous Deciparticle (TM) formulation of everolimus, dramatically reduces gastrointestinal drug accumulation compared with oral everolimus. Oral dosing drives extreme gut exposure—up to 2,448× plasma levels in the stomach—while IV Sapu003 limits GI tissue levels to just 36–48× plasma, representing reductions of up to 67-fold. The company stated that this shift may improve tolerability, maintain the drug’s intrinsic metabolic profile, and provide more consistent systemic exposure.

From checkout lanes to connected carts, the retail experience is being reinvented — and A2Z Cust2Mate Solutions (NASDAQ: AZ ) is at the forefront of the movement. A2Z develops and deploys “smart-cart” technology that aims to transform how consumers shop in physical stores by melding convenience, personalization and data intelligence into the traditional grocery-store cart.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability and established a clear recommended Phase 2 dose. Encouraging signals of durable disease control were observed, particularly in tumors with DNA damage repair pathway deficiencies. Building on these results, Lantern is advancing multiple biomarker-guided Phase 1b/2 trials across triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma. The company and independent analysts estimate LP-184’s aggregate market opportunity could exceed $10 billion annually.

Safe & Green Holdings (NASDAQ: SGBX), a diversified holding company, said its energy subsidiary Olenox Corp. has received its U.S. Department of Transportation (“DOT”) number and is preparing to mobilize its service division assets. The approval marks a procedural but necessary step for the company as it restarts its oilfield services operations and expands service capacity across its portfolio of wells ( https://ibn.fm/Ncnk5 ).

A2Z Cust2Mate Solutions (NASDAQ: AZ), a global smart retail technology company, said it entered an agreement with a premium grocery retailer operating more than 50 stores in Central America to deploy the A2Z Cust2mate smart cart platform. Initial rollout is planned for early 2026 in two flagship locations, with the shared goal of expanding to a full chain-wide deployment following successful implementation. The Company said the agreement marks a significant milestone for large-scale smart cart adoption in Central America, supported by its regional channel partner Trixo, and will help redefine the in-store experience, enhance retail media opportunities, and generate new data insights. CEO Gadi Graus said the collaboration represents a major leap for smart retail in the region and sets the stage for scalable adoption across the entire chain.

Micropolis AI Robotics (NYSE American: MCRP), a UAE-based developer of autonomous mobile robots and AI-driven security solutions, said it signed a non-binding Letter of Intent with QSS Robotics to establish a strategic collaboration for the distribution, localization, and deployment of Micropolis technologies across Saudi Arabia. The LOI outlines plans for commercial representation, joint engagement with government and private-sector customers, and integration and after-sales support under Micropolis supervision, building on agreements between the companies dating to 2022. Micropolis will provide its full suite of technologies, including M01 and M02 autonomous mobility platforms, Mission Planner and HD Mapping systems, Tele-Operator tools, and Microspot AI modules. QSS Robotics will act as Micropolis’ commercial and technical partner in the Kingdom. CEO Fareed Aljawhari said the agreement expands the Company’s reach in Saudi Arabia and reflects the strong alignment between the two companies.

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than 30 million Americans and the urgent need for new therapies. The article spotlights Soligenix’s late-stage development of HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma, now in its final confirmatory study before worldwide marketing submissions, and places the Company’s efforts at the intersection of advancing treatment options and emerging national health policy initiatives.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has secured its first state-level Department of Corrections contract in the United States, marking a new stage in its U.S. expansion. The contract, awarded under Arizona’s statewide Behavioral Health services program, will deploy the company’s GPS-based PureSecurity technology as part of broader rehabilitative and supervision services. Implementation is scheduled to begin in January 2026, according to the company’s announcement ( https://ibn.fm/yK21N ).

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study Group, held Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, which also reduces tau biomarkers linked to disease progression. Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications and underscoring that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the Company’s strategic path forward.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) formed a new business unit dedicated to driving the adoption of its quantum computing products and services within the U.S. government. Led by seasoned government and public sector business executive Jack Sears Jr., the newly established unit will support D-Wave’s enterprise-wide U.S. government-related initiative.

This article has been disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial Magnetic Stimulation for depression, including suicidal depression. The update follows evidence suggesting NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in symptom reduction and clinical response rates exceeding 80%. The Company noted NRX-101’s D-cycloserine component appears to augment neuroplasticity associated with TMS, while its low-dose lurasidone is intended to mitigate D-cycloserine’s known risk of low-grade hallucinations. NRx said it aims to validate the findings in a well-controlled trial of about 120 participants and is in partnership discussions with TMS device manufacturers to pursue joint registration studies and potential label augmentation.

Newton Golf Company (NASDAQ: NWTG), a leader in physics-based golf shaft technology, said it achieved the highest single-day sales total in its history on Black Friday, driven by demand for its Fast Motion and Motion shaft families, and confirmed that November 2025 marks its strongest November on record. The Company reported its largest-ever 24-hour volume of direct-to-consumer orders, supported by rising tour adoption, greater brand visibility, strong repeat customer engagement, and a surge of first-time buyers. CEO Greg Campbell said the results reflect growing enthusiasm for Newton’s technology, noting Fast Motion remains its most successful product launch to date.

China’s battery-car mastery is propelling its flying vehicle manufacturers ahead of global rivals. Expertise developed through years of electric vehicle production and unmanned aircraft development is giving domestic companies a distinct edge in the nascent aerial mobility market.

Quantum technology is moving from distant theory to something businesses and the public are starting to pay attention to. A new study called the Quantum Index Report 2025 shows how interest in quantum computing is growing, even though many people still do not fully understand it.

BYD, a Chinese electric vehicle maker, is looking to leverage its Blade Battery as a way to reduce the quantity of minerals needed during the manufacture of batteries for EVs. Its battery technology is specifically designed to reduce the amount of nickel and cobalt required in vehicle electrification, and in this way, boost sustainability efforts as the world transitions to greener forms of transport.

This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement.

A judge on the Michigan Court of Claims is set to review arguments over whether state lawmakers crossed a constitutional line when they approved a new tax on cannabis. The hearing centers on a 24% levy on wholesale cannabis transactions that became a key part of the state budget signed by Governor Gretchen Whitmer last month.

Disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising.

Massimo Group (NASDAQ: MAMO) said its Board approved adding Bitcoin as part of a long-term treasury reserve strategy, with initial purchases already begun and holdings to be disclosed in upcoming SEC filings or via Form 8-K. The Company said the program will be funded primarily through operating cash flows, with the option to use market instruments, and will employ institutional-grade custody with multi-signature cold storage and audit-ready controls. Massimo expects Bitcoin to represent a single-digit percentage of total assets over five years, positioning it as a strategic reserve rather than an operating asset. CEO David Shan said the move reflects a long-term view on liquidity diversification, inflation resilience and the maturation of digital asset infrastructure.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

HealthLynked (OTCQB: HLYK), an AI-driven global healthcare network focused on improving care coordination and reducing costs, appointed Chris G. Pulos of Marsh McLennan Agency and Jason Bishara of NSI Insurance Group to its Board. The Company said the additions bring decades of experience in employer benefits, payer strategy, insurance and risk management as HealthLynked expands collaborations with insurers, employer groups and healthcare organizations. Founder and CEO Dr. Michael Dent said their expertise will support national scaling of the HealthLynked Network and its AI platform, ARI, while strengthening governance ahead of a planned Nasdaq Capital Market listing.

OptimumBank Holdings (NYSE American: OPHC), a bank holding company that owns 100% of community bank OptimumBank, headquartered in Fort Lauderdale, Florida, reported another period of higher earnings, loan expansion, and deposit growth in the third quarter of 2025. The bank posted net income of $4.32 million, or $0.37 per basic share, according to its latest update ( https://ibn.fm/6jUHu ).

GlobalTech (OTC: GLTK), a U.S.-based technology holding company focused on AI, big data and emerging technologies, said it entered a definitive agreement to acquire a 51% interest in 123 Investments Limited d/b/a Moda in Pelle, a premium UK footwear brand with approximately $37 million in net revenue last year. The Company said the deal is expected to add a new revenue stream, strengthen its UK operational presence and enhance e-commerce capabilities through Thrivo AI integration, with closing expected within 30 days subject to customary conditions. CEO Dan Green said the acquisition aligns with GlobalTech’s value-creation strategy and will support technology deployment across both businesses. GlobalTech said the 51% stake will be purchased through a combination of common stock and Convertible Series A Preferred Stock, which convert to common stock upon a Nasdaq Capital Market uplisting or other specified conditions and carry no dividends.

HealthLynked (OTCQB: HLYK), an AI-driven global healthcare network focused on improving care coordination and reducing costs, appointed Chris G. Pulos of Marsh McLennan Agency and Jason Bishara of NSI Insurance Group to its Board. The Company said the additions bring decades of experience in employer benefits, payer strategy, insurance and risk management as HealthLynked expands collaborations with insurers, employer groups and healthcare organizations. Founder and CEO Dr. Michael Dent said their expertise will support national scaling of the HealthLynked Network and its AI platform, ARI, while strengthening governance ahead of a planned Nasdaq Capital Market listing.

Oncotelic Therapeutics (OTCQB: OTLC) said its 45%-owned joint venture, Sapu Nano, reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides—into sub-20 nm nanoparticles suitable for IV delivery. The Company said the findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 supply. CEO Dr. Vuong Trieu said the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates, with Sapu003 representing the first of a broader pipeline.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine formulation, deeming the submission “substantially complete” and assigning a July 29, 2026 review goal date. CEO Jonathan Javitt said KETAFREE is designed to provide a single-patient, preservative-free alternative to current multidose ketamine vials that contain Benzethonium Chloride, a compound no longer recognized as safe by the FDA. The Company said KETAFREE aligns with MAHA initiatives to remove toxic substances from medicines and supports domestic supply-chain priorities, with potential 2026 approved drug sales if approved on schedule. NRx noted the program is separate from NRX-100, its Fast Track-designated treatment for suicidal depression, and said it continues to advance its broader pipeline and HOPE Therapeutics clinics.

Stewards (OTC: SWRD), a diversified financial company operating across private credit, real assets and digital finance, appointed Scott McGowan as chief marketing officer to lead integrated marketing and communications as the Company expands its operating segments and advances toward a planned Nasdaq Capital Market uplisting. McGowan, formerly director of investor relations at InvestorBrandNetwork and previously CEO of a strategic communications consultancy, brings more than 20 years of experience advising growth-stage companies on brand positioning, capital-markets strategy and stakeholder engagement. President Shaun Quin said McGowan will strengthen transparency and unify messaging as Stewards enters its next phase of growth.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update conference call on Dec. 2, 2025, at 9 a.m. Eastern to review recent clinical, regulatory and operational developments.

European auto sales grew 4.9% in October as electric models outpaced gas and diesel counterparts for the first time. Data from the European Automobile Manufacturers’ Association (ACEA) captures a pivotal moment for an industry that has weathered multiple challenges throughout the year, from trade tensions to slower-than-expected technological transitions. According to the ACEA, registrations across the EU, Britain and EFTA countries reached 1.092 million units in October.

Last week saw the price of copper drop slightly, pressured by increasing expectations of a reduction in interest rates by the Federal Reserve and a firmer dollar. On the London Metal Exchange, three-month copper hit $10,780.50 per metric ton, representing a 0.2% increase.

The steep cost of healthcare in the U.S. has always been, and is becoming an even bigger political issue with each passing year. The issue was at the center of the recent shutdown of the federal government and the shutdown was only ended after a promise that the expiring healthcare subsidies would be voted on this month. Health insurance costs are soaring while citizens grapple with a high cost of living.

A new McKinsey Global Institute report offers a counterpoint to the widespread worry that AI will wipe out large segments of the workforce. While the research acknowledges that current tools could theoretically handle approximately 57% of tasks, the authors say this figure reflects what is technically possible, not what companies are likely to implement in practice.

Microsoft has secured renewable electricity supply from two Spanish solar facilities through an agreement with Madrid-based developer Zelestra . The power purchase arrangement includes funding for community sustainability programs through nonprofit organization ECODES, linking clean energy procurement with local social impact initiatives in a model that’s increasingly being adopted by technology companies.

Japan is moving to tighten safeguards in its digital asset industry by preparing rules that would force crypto exchanges to maintain reserves for potential customer losses.

YouTube is bringing back private messaging inside its mobile app, six years after removing the feature. The company has started testing a new video-sharing and chat tool for users aged 18 and above in Ireland and Poland. This test allows people to share long videos, Shorts, and live streams directly within the YouTube app, making it easier to discuss content without switching to other apps like WhatsApp or Instagram.

BioMedWire Editorial Coverage : Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) ( Profile ), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix’s work sits at a critical intersection of medical innovation and national health priorities. The company is working alongside several leading companies committed to making an impact in the pharmaceutical and life sciences space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…

Cannabis retailers across the U.S. are adjusting to an unexpected shift in shopper behavior as the youngest legal buyers reshape the market. Gen Z customers are coming into stores, but they are approaching cannabis with more intention, more research, and more caution than many of the shoppers who came before them.